Programs in Medical Technology

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development pr...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

- Data Presented at the American Association for Cancer Research - PRINCETON, N.J., April 21 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced preclinical efficacy and safety data from multiple programs, including antibodies to novel and potentially important cancer ta...

Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets

ATLANTA, Feb. 10 /PRNewswire/ -- Food retailers concerned about pathogens such as Salmonella, Listeria, and E. coli in their perishable departments can now outsource "deep cleaning" services to Chemstar Corporation, a company that operates food safety and sanitation programs throughout the Uni...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced positive pr...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced changes to conserve the Company's resources, focus its efforts on its late-stage obesity programs and realign its management team. The key aspects of these changes are as follows: ...

Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the t...

Behavioral Modification Programs Help Obese Children Manage Their Weight

ROCKVILLE, Md., Sept. 29 /PRNewswire-USNewswire/ -- Obese school-age kids and teens can lose weight or prevent further weight gain if they participate in medium- to high-intensity behavioral management programs, according to a new report released today by HHS' Agency for Healthcare Research an...

Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO'08

SAN DIEGO, June 18 /PRNewswire/ -- Kansas researchers and companies excel in the human health biosciences, and $3.7 million in new Kansas Bioscience Authority (KBA) investments in that sector will support cutting-edge innovations for the treatment of cancer, HIV, and osteoporosis, as well as i...

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that multiple abstracts featuring its lead oncology products will be featured at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - Jun...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demo...

Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)

CAMBRIDGE, Mass., and MILAN, Italy, April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced preclinical data f...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM ) today announced that the Company will focus on its new drug discovery programs targeting Hepatitis C, and drug-resistant bacterial and fungal infections, and will discontinue all development programs for pa...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITI's family o...

TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY

New AcuCare Programs Automate the Interface between Health Assessments for Patients and the Generation of Customized Care Treatment Plans AUBURN, Calif., Jan. 22 /PRNewswire/ -- TCS Healthcare Technologies, an industry leader in the development of medical management software applications th...

Genta Clinical Programs Featured at American Society of Hematology Meeting

Phase 3 CLL Survival Analysis Selected for ASH Press Briefing BERKELEY HEIGHTS, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) announced that several abstracts related to the Company's clinical programs will be featured at the annual meeting of the American Soc...

Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections

BOSTON, Oct. 25 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has closed the first tranche of a $40 million private financing. Aisling Capital led the round, with additional participation by new investors, D.E. Shaw and Boston Life Science Venture Corporation, and curre...

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases

WATERTOWN, Mass., Oct. 17 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer's, Schizophrenia and Huntington's diseases. EnVivo Phar...

Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations

ASHBURN, Va., Sept. 26 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations: - Three Investigational New Drug (IND) Application...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to ...

Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs

CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc. ( http://www.neuronascent.com ) announced today that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer's disease, depression and ischemia. Neurona...

Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs

American Association for Cancer Research Aims to Raise Awareness about the Importance of Clinical Trial Participation PHILADELPHIA, Sept. 24 /PRNewswire/ -- News facts: -- Most Americans with cancer would be receptive to participating in clinical trials if they knew about them. ...

Portola Completes $60 Million Financing to Advance Its Therapeutic Programs

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred s...

Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs

Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the...

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

- Company on Schedule to Have Two Follow-on Biologics in Clinical Studies by Year-End - Enrollment On Track in MMD Clinical Study - ALS Expanded Access Program Continues to Enroll - Insmed Generates $2.3 million in Cost Recovery Revenue Through...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of two large Ambulatory Blood Pressure Monitoring (A...

Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs

NEW YORK, Dec. 19 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the trea...

Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

ROCKVILLE, Md., Nov. 12 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today reported financial results for the third quarter ended September 30, 2007 and reviewed its recent accomplishments and upcoming milestones. Novavax reported a net loss of $9.0 million, or the equivalent of $0.15...

PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs

DES MOINES, Iowa, Oct. 16 /PRNewswire/ -- Protocol Driven Healthcare, Inc. (PDHI) today launched ConXus(R) Rewards and announced a partnership with Hallmark Insights to provide fully integrated incentive management and fulfillment services to users of the ConXus health improvement platform. C...

Raptor Pharmaceuticals Provides Update of Product Programs

Poster at Upcoming International Liver Cancer Conference Status of Ongoing Programs Regulatory Consulting Firm Retained NOVATO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board...

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

- Enrollment completed in Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis - - Continued focus to define registrational path for belinostat in the treatment of cancer - - Conference call and webcast to be held ...

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $3.1 million, compared with revenues of $7.3 million for the second quarter of 2006. The net loss for...

ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research

SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present ...

Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio SOUTH SAN FRANCISCO, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced the presentation of four research projects aimed at identifying small molecule inhibitors of select kinases as potential therapeutics for ...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

- New Study Demonstrated the Clinical Potential of Peregrine's Unique Selective Anti-VEGF Antibodies, Which Were as Effective as Avastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company ...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced that seven abstracts will be presented at the 2007 Pediatric Academic Societies' (PAS) Annual Meeting demonstrating the company's commitment to advancing the science of pediatric medicine. Data are fro...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model of normal human skin found that Menadione was the only agent capable of abrogating the cytotoxic effect of erlotinib * Phase I single agent Marqibo(r) showed OPTISOME(tm) agent was generally well tolerated in metastatic melanoma patients w...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that data featuring its approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline candidates will be presented at the American Diabetes Ass...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...provides a full range of inpatient and outpatient services. It is the largest pediatric ophthalmology program in the nation with multiple subspecialty programs that are considered to be among today's finest resources for diagnosis, treatment and research. Founded in 1901, Children's Hospital Los Angele...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ses associated with the expansion of the Company's programs as discussed in more detail in the "Operating Expe...to build its team to support its internal microRNA programs and its GSK collaboration. Regulus generated a lo... addition to our clinical programs, we have active programs in many different therapeutic areas as well as est...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

...icket sales in the (RED)ZONE will benefit HIV/AIDS programs in Africa supported by the Global Fund. "I ...om that product to the Global Fund to finance AIDS programs in Africa, with an emphasis on the health of women...he Global Fund has become the dominant financer of programs to fight AIDS, tuberculosis and malaria, with appr...